Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | RAD52 | P43351 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 2/20 | 0.45 |
| ▸ | SLC9A3 | P48764 | 5/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | ATP4A | P20648 | 1/20 | 0.41 |
| ▸ | ATP4B | P51164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695775 | 0.84 | KMT2A (0.65) | KMT2ARAD52POLBMEN1ALDH1A1 | |
| SCHEMBL6695760 | 0.81 | KMT2A (0.97) | KMT2ARAD52POLBMEN1ALDH1A1 | |
| SCHEMBL6693942 | 0.78 | RAD52 (0.74) | KMT2ARAD52POLBMEN1ALDH1A1 | |
| SCHEMBL3488823 | 0.77 | ADORA2A (0.51) | ALDH1A1MAPTKDM4EFABP4FABP5 | |
| SCHEMBL6694553 | 0.77 | KMT2A (0.81) | KMT2ARAD52POLBMEN1ALDH1A1 | |
| SCHEMBL3486244 | 0.77 | KDM4E (0.50) | KMT2ARAD52POLBMEN1ALDH1A1 | |
| SCHEMBL6696507 | 0.77 | RAD52 (0.51) | KMT2ARAD52POLBMEN1ALDH1A1 | |
| SCHEMBL6691724 | 0.76 | RAD52 (0.50) | KMT2ARAD52POLBMEN1ALDH1A1 | |
| SCHEMBL6696024 | 0.74 | MAPT (0.46) | KMT2ARAD52POLBMEN1ALDH1A1 | |
| SCHEMBL6693510 | 0.74 | RAD52 (1.00) | KMT2ARAD52POLBMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | MERCK PATENT GMBH (DE) | 2004-11-11 | — | — | US | claimed |
| CN-1422260-A | 2-guanidino-4-arylchinazolines as NHE-3 inhibitors | MERCK PATENT GMBH (DE) | 2003-06-04 | — | — | CN | claimed |
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | MERCK PATENT GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| CN-1422260-A | 2-guanidino-4-arylchinazolines as NHE-3 inhibitors | MERCK PATENT GMBH (DE) | 2003-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | NHERF1, SLC9A3, SLC9A1 | KMT2A 3326/4885RAD52 4856/4885POLB 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.